

Document made available under the Patent Cooperation Treaty (PCT)

International application number: PCT/US04/043451

International filing date: 22 December 2004 (22.12.2004)

Document type: Certified copy of priority document

Document details: Country/Office: US
Number: 60/532,243
Filing date: 23 December 2003 (23.12.2003)


Date of receipt at the International Bureau: 09 February 2005 (09.02.2005)

Remark: Priority document submitted or transmitted to the International Bureau in compliance with Rule 17.1(a) or (b)



World Intellectual Property Organization (WIPO) - Geneva, Switzerland
Organisation Mondiale de la Propriété Intellectuelle (OMPI) - Genève, Suisse

1277192



THE UNITED STATES OF AMERICA

TO ALL TO WHOM THESE PRESENTS SHALL COME:

UNITED STATES DEPARTMENT OF COMMERCE

United States Patent and Trademark Office

January 24, 2005

THIS IS TO CERTIFY THAT ANNEXED HERETO IS A TRUE COPY FROM
THE RECORDS OF THE UNITED STATES PATENT AND TRADEMARK
OFFICE OF THOSE PAPERS OF THE BELOW IDENTIFIED PATENT
APPLICATION THAT MET THE REQUIREMENTS TO BE GRANTED A
FILING DATE.

APPLICATION NUMBER: 60/532,243

FILING DATE: *December 23, 2003*

RELATED PCT APPLICATION NUMBER: *PCT/US04/43451*



Certified by

Under Secretary of Commerce
for Intellectual Property
and Director of the United States
Patent and Trademark Office

16988
16988
U.S.P.T.O.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

MAIL STOP PROVISIONAL APPLICATION

Assistant Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

15555 U.S.P.T.O.
60/532243

122303

PROVISIONAL APPLICATION COVER SHEET

Sir:

This is a request for filing a **PROVISIONAL APPLICATION FOR PATENT** under 37 CFR 1.53(c).

Docket Number			CL001487-P
INVENTOR(s) / APPLICANT(s)			
Last Name	First Name	Middle Name	RESIDENCE (City and either State or Foreign Country)
GRAUPE	Michael		Pacifica, CA - U.S.A.
LAU	Agnes	J.	San Francisco, CA - U.S.A.
LI	Jiayao		Foster City, CA - U.S.A.
LINK	John	O.	San Francisco, CA - U.S.A.
MOSSMAN	Craig	J.	Campbell, CA - U.S.A.
WOO	Soon	H.	Palo Alto, CA - U.S.A.
ZIPFEL	Sheila	M.	Mountain View, CA - U.S.A.
TITLE OF THE INVENTION			
AMIDINO COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS			
CORRESPONDENCE ADDRESS			
Customer Number or Bar Code Label	23519 <small>(Insert Customer No. or Attach bar code label here)</small>		or Correspondence address below
ENCLOSED APPLICATION PARTS (check all that apply)			
43 Pages Specification	[X] Other (specify): Title Page Certificate of		
9 Pages Claims (Optional)	Mailing		
1 Page Abstract (Optional)	Return Postcard		
METHOD OF PAYMENT (check one)			
[] A check is enclosed to cover the Provisional Filing Fee [X] The Commissioner is hereby authorized to charge filing fees and credit Deposit Account Number: 50-0970		PROVISIONAL FILING FEE AMOUNT (\$)	\$160.00


Was the invention made by an agency of the United States Government or under a contract with an agency of the United States Government?

[X] No.

[] Yes, the name of the U.S. Government agency and the Government contract number are: _____

The above FEE is believed to be correct. However, the Commissioner is authorized to charge any deficiencies or credit any overpayments to Deposit Account No. 50-0970.

Respectfully submitted,


Rekha Bansal, Reg. No. 36,440

Date: December 23, 2003

Express Mail Label No. EV151048566US

Date of Deposit: December 23, 2003

I hereby certify that this is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated below and is addressed to Mail Stop Provisional Application, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

By: Debra K. Bowen Date: Dec. 23, 2003
Debra K. Bowen

AMIDINO COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS

Inventors

Michael Graupe

Agnes Lau

Jiayao Li

John O. Link

Craig J. Mossman

Soon H. Woo

Sheila M. Zipfel

AMIDINO COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS

Field of the Invention

The present invention is directed to compounds that are inhibitors of cysteine proteases, in particular, cathepsins B, K, L, F, and S and are therefore useful in treating diseases mediated by these proteases. The present invention is directed to pharmaceutical compositions comprising these compounds and processes for preparing them.

State of the Art

Cysteine proteases represent a class of peptidases characterized by the presence of a cysteine residue in the catalytic site of the enzyme. Cysteine proteases are associated with the normal degradation and processing of proteins. The aberrant activity of cysteine proteases, e.g., as a result of increased expression or enhanced activation, however, may have pathological consequences. In this regard, certain cysteine proteases are associated with a number of disease states, including arthritis, muscular dystrophy, inflammation, tumor invasion, glomerulonephritis, malaria, periodontal disease, metachromatic leukodystrophy, and others. For example, increased cathepsin B levels and redistribution of the enzyme are found in tumors; thus, suggesting a role for the enzyme in tumor invasion and metastasis. In addition, aberrant cathepsin B activity is implicated in such disease states as rheumatoid arthritis, osteoarthritis, pneumocystis carinii, acute pancreatitis, inflammatory airway disease and bone and joint disorders.

The prominent expression of cathepsin K in osteoclasts and osteoclast-related multinucleated cells and its high collagenolytic activity suggest that the enzyme is involved in ososteoclast-mediated bone resorption and, hence, in bone abnormalities such as occurs in osteoporosis. In addition, cathepsin K expression in the lung and its elastinolytic activity suggest that the enzyme plays a role in pulmonary disorders as well.

Cathepsin L is implicated in normal lysosomal proteolysis as well as several disease states, including, but not limited to, metastasis of melanomas. Cathepsin S is implicated in Alzheimer's disease and certain autoimmune disorders, including, but not limited to juvenile onset diabetes, multiple sclerosis, pemphigus vulgaris, Graves' disease, myasthenia gravis, systemic lupus erythematosus, rheumatoid arthritis and Hashimoto's thyroiditis. In addition, cathepsin S is implicated in: allergic disorders, including, but not limited to asthma; and allogeneic immune responses, including, but not limited to, rejection of organ transplants or tissue grafts.


Another cysteine protease, Cathepsin F, has been found in macrophages and is involved in antigen processing. It is believed that Cathepsin F in stimulated lung macrophages and possibly other antigen presenting cells could play a role in airway inflammation (see G. P. Shi et al, *J. Exp. Med.* 2000, 191,1177)

5 In view of the number of diseases wherein it is recognized that an increase in cysteine protease activity contributes to the pathology and/or symptomatology of the disease, molecules which inhibit the activity of this class of enzymes, in particular molecules which inhibit cathepsins B, K, L, F, and/or S, will therefore be useful as therapeutic agents.

10

SUMMARY OF THE INVENTION

In one aspect, this invention is directed to a compound of Formula (I):



wherein:

15 R^1 is benzoxazol-2-yl, oxazolo[4,5-b]pyridin-2-yl, 2-ethyl-[1,3,4]-oxadiazol-5-yl, 2-phenyl-[1,3,4]-oxadiazol-5-yl, 3-phenyl-[1,2,4]-oxadiazol-5-yl, 3-thien-3-yl-[1,2,4]-oxadiazol-5-yl, 3-pyridin-3-yl-[1,2,4]-oxadiazol-5-yl, 3-ethyl-[1,2,4]-oxadiazol-5-yl, 5-ethyl-[1,2,4]-oxadiazol-3-yl, or 2-methoxymethyl-[1,3,4]-oxadiazol-5-yl; and

R^2 is ethyl or *n*-propyl;

20 R^3 is cyclohexylmethyl, 1-methylcyclohexylmethyl, cyclopentylmethyl, 1-methylcyclopentylmethyl, cyclopropylmethylsulfinylmethyl, cyclopropylmethylsulfonylmethyl, 2-phenylsulfanylethyl, 2-phenylsulfonylethyl, pyridin-2-ylmethylsulfonylmethyl, benzylsulfinylmethyl, benzylsulfonylmethyl, 2-(difluoromethoxy)-benzylsulfonylmethyl, or 2-chlorobenzyl;

25 R^4 is methyl, phenyl, 4-fluorophenyl, isopropylamine, cyclopentylamine, tetrahydropyran-4-yl, morpholin-4-yl, or pyrrolidin-1-yl;









R^5 is methylsulfonyl, 2,2,2-trifluoroethyl, ethoxycarbonyl, or pyridin-3-ylsulfonyl; or











R^4 and R^5 together with the atoms to which they are attached form 1,1-dioxo-benzo[d]isothiazol-3-yl or 1,1-dioxo-1,4-dihydro- λ^6 -benzo[1,2,4]thiadiazin-3-yl; or


a pharmaceutically acceptable salt thereof.


Preferably, R³ is 1-methylcyclopentylmethyl.


Preferably, a compound selected from the group consisting of:















or a pharmaceutically acceptable salt thereof.

Preferably,



In a second aspect this invention is directed to a pharmaceutical composition comprising a

compound of the invention or a pharmaceutically acceptable salt thereof, in admixture with one or
5 more suitable excipients.

In a third aspect this invention is directed to a method for treating a disease in an animal
mediated by cysteine proteases, in particular cathepsin S, which method comprises administering to
the animal a therapeutically effective amount of compound of this invention or a pharmaceutically
acceptable salt thereof.

10 In a fourth aspect this invention is directed to a method of treating a patient undergoing a
therapy wherein the therapy causes an immune response in the patient comprising administering to
the patient a compound of this invention. Preferably, the immune response is mediated by MHC
class II molecules. The compound of this invention can be administered prior to, simultaneously, or
after the therapy. Preferably, the therapy involves treatment with a biologic. Preferably, the

15 therapy involves treatment with a small molecule.

Preferably, the biologic is a protein or an antibody, preferably a monoclonal antibody. More
preferably, the biologic is Remicade®, Refacto®, Referon-A®, Factor VIII, Factor VII, Betaseron®,
Epopgen®, Embrel®, Interferon beta, Botox®, Fabrazyme®, Elspar®, Cerezyme®, Myobloc®,
Aldurazyme®, Verluma®, Interferon alpha, Humira®, Aranesp®, Zevalin® or OKT3.

20 Preferably, the treatment involves use of heparin, low molecular weight heparin,
procainamide or hydralazine.

In a fifth aspect, this invention is directed to a method of treating immune response in an
animal that is caused by administration of a biologic to the animal which method comprises
administering to the animal in need of such treatment a therapeutically effective amount of a
25 compound of this invention.

In a sixth aspect, this invention is directed to a method of conducting a clinical trial for a

biologic comprising administering to an individual participating in the clinical trial a compound of this invention with the biologic.

In a seventh aspect, this invention is directed to a method of prophylactically treating a person undergoing treatment with a biologic with a compound of this invention to treat the immune response caused by the biologic in the person.

In an eighth aspect, this invention is directed to a method of determining the loss in the efficacy of a biologic in an animal due to the immune response caused by the biologic comprising administering the biologic to the animal in the presence and absence of a compound of this invention.

10 In a ninth aspect, this invention is directed to a method of improving efficacy of a biologic in an animal comprising administering the biologic to the animal with a compound of this invention.

In a tenth aspect, this invention is directed to the use of a compound of this invention for the manufacture of a medicament for combination therapy with a biologic, wherein the compound of this invention treats the immune response caused by the biologic.

15

DETAILED DESCRIPTION OF THE INVENTION

Definitions:

Unless otherwise stated, the following terms used in the specification and claims are defined for the purposes of this Application and have the following meanings.

20 "Animal" includes humans, non-human mammals (e.g., dogs, cats, rabbits, cattle, horses, sheep, goats, swine, deer, and the like) and non-mammals (e.g., birds, and the like).

"Biologic" means a therapeutic agent originally derived from living organisms for the treatment or management of a disease. Examples include, but are not limited to, proteins (recombinant and plasma derived), monoclonal or polyclonal, humanized or murine antibodies, 25 toxins, hormones, and the like. Biologics are currently available for the treatment of a variety of diseases such as cancer, rheumatoid arthritis, and haemophilia.

"Disease" specifically includes any unhealthy condition of an animal or part thereof and includes an unhealthy condition that may be caused by, or incident to, medical or veterinary therapy applied to that animal, i.e., the "side effects" of such therapy.

30 "Immune response" as used herein means an immune response that prevents effective treatment of a patient or causes disease in a patient. As an example, dosing a patient with a murine

antibody either as a therapy or a diagnostic agent causes the production of human antimouse antibodies that prevent or interfere with subsequent treatments. The incidence of antibody formation versus pure murine monoclonals can exceed 70%. (see Khazaeli, M. B. et al. "Human immune response to monoclonal antibodies", *J. Immunother.* 1994, 15, 42-52; Dillman R. O. et al. 5 "Human anti-mouse antibody response in cancer patients following single low-dose injections of radiolabeled murine monoclonal antibodies". *Cancer Biother.* 1994, 9, 17-28; and Reinsberg, J. "Interference by human antibodies with tumor marker assays". *Hybridoma.* 1995, 14, 205-208). Additional examples of known agent that suffer from deleterious immune responses are blood-clotting factors such as factor VIII. When administered to hemophilia A patients, factor VIII 10 restores the ability of the blood to clot. Although factor VIII is a human protein, it still elicits an immune response in hemophiliacs as endogenous factor VIII is not present in their blood and thus it appears as a foreign antigen to the immune system. Approximately 29-33% of new patients will produce antibodies that bind and neutralize the therapeutically administered factor VIII (see Lusher J. M. First and second generation recombinant factor VIII concentrates in previous untreated 15 patients: recovery, safety efficacy, and inhibitor development. *Semin Thromb Hemost.* 2002, 28(3), 273-276). These neutralizing antibodies require the administration of larger amounts of factor VIII in order to maintain normal blood clotting parameters; an expensive regimen of treatment in order to induce immune tolerance (see Briet E et al. The incidence of inhibitors in hemophilia A and the induction of immune tolerance. *Adv. Exp. Med. Bio.* 2001, 489, 89-97). Another immunogenic 20 example is adenoviral vectors. Retroviral therapy remains experimental and is of limited utility. One reason is that the application of a therapeutic virus generates an immune response capable of blocking any subsequent administration of the same or similar virus (see Yiping Yang et al. Cellular and Humoral Immune Responses to Viral Antigen Create Barrier to Lung-Directed Gene Therapy with Recombinant Adenoviruses. *J. of Virology.* 1995, 69, 2004-2015). This ensures that retroviral 25 therapies must be based on the transient expression of a protein or the direct incorporation of viral sequence into the host genome. Directed research has identified multiple viral neutralizing epitopes recognized by host antibodies (see Hanne, Gahery-Segard et al. Immune Response to Recombinant Capsid Proteins of Adenovirus in Humans: Antifiber and Anti-Penton Base Antibodies has a Synergistic Effect on Neutralizing Activity. *J. of Virology* 1998. 72, 2388-2397) suggesting that 30 viral modifications will not be sufficient to overcome this obstacle. This invention will enable a process whereby an adenoviral therapy will have utility for repeated application. Another example

of an immunogenic agent that elicits neutralizing antibodies is the well-known cosmetic agent Botox. Botulin toxin protein, is purified from the fermentation of *Clostridium botulinum*. As a therapeutic agent, it is used for muscle disorders such as cervical dystonia in addition to cosmetic application. After repeated exposure patients generate neutralizing antibodies to the toxin that results in reduced efficacy (see Birklein F. et al. Sudomotor testing predicts the presence of neutralizing botulinum A toxin antibodies. *Ann Neurol.* 2002, 52, 68-73 and Rollnik, J. D. et al. Neutraling botulinum toxic type a antibodies: clinical observations in patient with cervical dystonia. *Neurol. Clin. Neurophysiol.* 2001, 2001(3), 2-4).

Immune response also encompasses diseases caused by the biologic agents. A specific example of this is the immune response to therapy with recombinant human erythropoietin (EPO). Erythropoietin is used to stimulate the growth of red cells and restore red blood cell counts in patients who have undergone chemotherapy or dialysis. A small percentage of patients develop antibodies to EPO and subsequently are unresponsive to both therapeutically administered EPO and their own endogenous EPO (see Casadevall, N. et al., Pure red-cell aplasia and anti-erythropoietin antibodies in patients treated with recombinant erythropoietin. *NEJM.* 2002, 346:469-475). They contract a disorder, pure red cell aplasia, in which red blood cell production is severely diminished (see Gershon S. K. et. al. Pure red-cell aplasia and recombinant erythropoietin. *NEJM.* 2002, 346:1584-1586). This complication of EPO therapy is lethal if untreated. Another specific example is the murine antibody, OKT3 (a.k.a., Orthoclone) a monoclonal antibody directed towards CD-3 domain of activated T-cells. In clinical trials 20-40% of patients administered OKT3 produce antibodies versus the therapy. In addition to neutralizing the therapy these antibodies also stimulate a strong host immune reaction. The immune reaction is severe enough that patients with high titers of human anti-mouse antibodies are specifically restricted from taking the drug (see Orthoclone package label). A final example is a human antibody therapeutic. Humira® is a monoclonal antibody directed against TNF and is used to treat rheumatoid arthritis patients. When taken alone ~12% of patients develop neutralizing antibodies. In addition, a small percentage of patients given the drug also contract a systemic lupus erythematosus-like condition that is an IgG-mediated immune response induced by the therapeutic agent (see Humira package label).

"Derived" means a similar agent can be traced to.

"Isomers" mean compounds of Formula (I) having identical molecular formulae but differ in the nature or sequence of bonding of their atoms or in the arrangement of their atoms in space.

Isomers that differ in the arrangement of their atoms in space are termed "stereoisomers". Stereoisomers that are not mirror images of one another are termed "diastereomers" and stereoisomers that are nonsuperimposable mirror images are termed "enantiomers" or sometimes "optical isomers". A carbon atom bonded to four nonidentical substituents is termed a "chiral center". A compound with one chiral center has two enantiomeric forms of opposite chirality is termed a "racemic mixture". A compound that has more than one chiral center has 2^n ¹ enantiomeric pairs, where n is the number of chiral centers. Compounds with more than one chiral center may exist as either an individual diastereomers or as a mixture of diastereomers, termed a "diastereomeric mixture". When one chiral center is present a stereoisomer may be characterized by the absolute configuration of that chiral center. Absolute configuration refers to the arrangement in space of the substituents attached to the chiral center. Enantiomers are characterized by the absolute configuration of their chiral centers and described by the *R*- and *S*-sequencing rules of Cahn, Ingold and Prelog. Conventions for stereochemical nomenclature, methods for the determination of stereochemistry and the separation of stereoisomers are well known in the art (e.g., see "Advanced Organic Chemistry", 4th edition, March, Jerry, John Wiley & Sons, New York, 1992). It is understood that the names and illustration used in this Application to describe compounds of Formula (I) are meant to be encompassed all possible stereoisomers.

"Pathology" of a disease means the essential nature, causes and development of the disease as well as the structural and functional changes that result from the disease processes.

"Pharmaceutically acceptable" means that which is useful in preparing a pharmaceutical composition that is generally safe, non-toxic and neither biologically nor otherwise undesirable and includes that which is acceptable for veterinary use as well as human pharmaceutical use.


"Pharmaceutically acceptable salts" means salts of compounds of Formula (I) which are pharmaceutically acceptable, as defined above, and which possess the desired pharmacological activity. Such salts include acid addition salts formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like; or with organic acids such as acetic acid, propionic acid, hexanoic acid, heptanoic acid, cyclopentanepropionic acid, glycolic acid, pyruvic acid, lactic acid, malonic acid, succinic acid, malic acid, maleic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, *o*-(4-hydroxybenzoyl)benzoic acid, cinnamic acid, mandelic acid, methylsulfonic acid, ethanesulfonic acid, 1,2-ethanedisulfonic acid, 2-hydroxyethanesulfonic acid, benzenesulfonic acid, *p*-chlorobenzenesulfonic acid,

2-naphthalenesulfonic acid, *p*-toluenesulfonic acid, camphorsulfonic acid,
4-methylbicyclo[2.2.2]oct-2-ene-1-carboxylic acid, glucoheptonic acid,
4,4'-methylenebis(3-hydroxy-2-ene-1-carboxylic acid), 3-phenylpropionic acid, trimethylacetic
acid, tertiary butylacetic acid, lauryl sulfuric acid, gluconic acid, glutamic acid, hydroxynaphthoic
acid, salicylic acid, stearic acid, muconic acid and the like.

Pharmaceutically acceptable salts also include base addition salts which may be formed when acidic protons present are capable of reacting with inorganic or organic bases. Acceptable inorganic bases include sodium hydroxide, sodium carbonate, potassium hydroxide, aluminum hydroxide and calcium hydroxide. Acceptable organic bases include ethanolamine, diethanolamine, triethanolamine, tromethamine, *N*-methylglucamine and the like.

The present invention also includes prodrugs of a compound of Formula (I). Prodrug means a compound that is convertible in vivo by metabolic means (e.g. by hydrolysis) to a compound of Formula (I).

Compounds of Formula (I) may exist as tautomers. Such tautomeric forms (individual
tautomers or mixtures thereof) are within the scope of this invention. For example, a compound of
Formula (I) where can tautomerize to give a compound of Formula (I') and vice versa as shown
below.



20 It will be recognized by a person skilled in the art that the amount of tautomers will vary based on certain conditions such as steric interactions, electronic effects of substituents, solvent polarity, hydrogen bonding capability, temperature, pH, and the like.

"Therapeutically effective amount" means that amount which, when administered to an animal for treating a disease, is sufficient to effect such treatment for the disease.

25 "Treatment" or "treating" means any administration of a compound of the present invention
and includes:

- (1) preventing the disease from occurring in an animal which may be predisposed to the disease but does not yet experience or display the pathology or symptomatology of the disease,

(2) inhibiting the disease in an animal that is experiencing or displaying the pathology or

symptomatology of the diseased (i.e., arresting further development of the pathology and/or symptomatology), or

(3) ameliorating the disease in an animal that is experiencing or displaying the pathology or symptomatology of the diseased (i.e., reversing the pathology and/or symptomatology).

5 "Treatment" or "treating" with respect to combination therapy i.e., use with a biologic means any administration of a compound of the present invention and includes:

(1) preventing the immune response from occurring in an animal which may be predisposed to the immune response but does not yet experience or display the pathology or symptomatology of the immune response,

10 (2) inhibiting the immune response in an animal that is experiencing or displaying the pathology or symptomatology of the immune response (i.e., arresting further development of the pathology and/or symptomatology), or

(3) ameliorating the immune response in an animal that is experiencing or displaying the pathology or symptomatology of the immune response (i.e., reducing in degree or severity, or extent

15 or duration, the overt manifestations of the immune response or reversing the pathology and/or symptomatology e.g., reduced binding and presentation of antigenic peptides by MHC class II molecules, reduced activation of T-cells and B-cells, reduced humoral and cell-mediated responses and, as appropriate to the particular immune response, reduced inflammation, congestion, pain, necrosis, reduced loss in the efficacy of a biologic agent, and the like).

20

GENERAL SYNTHETIC SCHEME

Compounds of this invention can be made by the methods depicted in the reaction schemes shown below.

The starting materials and reagents used in preparing these compounds are either available
25 from commercial suppliers such as Aldrich Chemical Co., (Milwaukee, Wis.), Bachem (Torrance, Calif.), or Sigma (St. Louis, Mo.) or are prepared by methods known to those skilled in the art following procedures set forth in references such as Fieser and Fieser's Reagents for Organic Synthesis, Volumes 1-17 (John Wiley and Sons, 1991); Rodd's Chemistry of Carbon Compounds, Volumes 1-5 and Supplements (Elsevier Science Publishers, 1989); Organic Reactions, Volumes 30 1-40 (John Wiley and Sons, 1991), March's Advanced Organic Chemistry, (John Wiley and Sons, 4th Edition) and Larock's Comprehensive Organic Transformations (VCH Publishers Inc., 1989).


These schemes are merely illustrative of some methods by which the compounds of this invention can be synthesized, and various modifications to these schemes can be made and will be suggested to one skilled in the art having referred to this disclosure.

The starting materials and the intermediates of the reaction may be isolated and purified if desired using conventional techniques, including but not limited to filtration, distillation, crystallization, chromatography and the like. Such materials may be characterized using conventional means, including physical constants and spectral data.

Unless specified to the contrary, the reactions described herein take place at atmospheric pressure over a temperature range from about -78 °C to about 150 °C, more preferably from about 0 °C to about 125 °C and most preferably at about room (or ambient) temperature, e.g., about 20 °C. In the reactions described hereinafter it may be necessary to protect reactive functional groups, for example hydroxy, amino, imino, thio or carboxy groups, where these are desired in the final product, to avoid their unwanted participation in the reactions. Conventional protecting groups may be used in accordance with standard practice, for examples see T.W. Greene and P. G. M. Wuts in "Protective Groups in Organic Chemistry" John Wiley and Sons, 1991. Compound of Formula (Ia) and (Ib) can be prepared by the procedures described in Schemes 1-4 below.

Compounds of Formula (I) where R¹-R⁵ are as defined in the Summary of the Invention can be prepared by proceeding as in the following reaction Scheme 1 below.

Scheme 1



Reaction of a compound of formula (a) where LG is a leaving group such as halo with an amino acid compound of formula (b) (where R' is hydrogen or alkyl) provides a compound of formula (c) which is then converted to a compound of Formula (I). The reaction is carried out by

methods well known in the art. Some such methods are described in Dunn, A. D., *Org. Prep. Proceed. Int.*, 1998, 30, 709; Lindstroem, S., et al., *Heterocycles*, 1994, 38, 529; Katritzky, A. R., et al., *Synthesis*, 1990, 561; Hontz, A. C., et al., *Org. Synth.*, 1963, IV, 383; and Stephen, H., *J. Chem. Soc.*, 1957, 490.

- 5 Compounds of formula (a) are either commercially available or they can be readily prepared by methods well known in the art. Some such methods are described in working examples below. Amino acids of formula (b) are commercially available. Others can be prepared by methods well known in the art. Some such methods are described in PCT Application Publication Nos. WO 00/55144, WO 01/19816, WO 02/20485, WO 03/029200, U.S. Provisional Application No. 10 60/422,337, U. S. Patent No. 6,353,017B1, 6,492,662B1, 353,017 B1 and 6,525,036B1, the disclosures of which are incorporated herein by reference in their entirety.


Hydrolysis of the ester group where R' is alkyl under basic hydrolysis reacgction conditions, followed by the reaction of the resulting acid with a compound of formula (d) provides a compound of formula (e). The reaction can be effected with an appropriate coupling agent (e.g.,

- 15 benzotriazol-1-yloxy-trispyrrolidinophosphonium hexafluorophosphate (PyBOP[®]), 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDCI), *O*-(7-azabenzotriazol-1-yl)-1,1,3,3, tetra-methyluronium-hexafluorophosphate (HATU), *O*-benzotriazol-1-yl-
20 *N,N,N',N'*-tetramethyl-uronium hexafluorophosphate (HTBU), 1,3-dicyclohexylcarbodiimide (DCC), or the like) and optionally an appropriate catalyst (e.g., 1-hydroxybenzotriazole (HOBT), 1-hydroxy-7-azabenzotriazole (HOAt), or the like) and non-nucleophilic base (e.g., triethylamine, *N*-methylmorpholine, and the like, or any suitable combination thereof) at ambient temperature and requires 5 to 10 h to complete. Suitable reaction solvents include, but are not limited to, dimethylformamide, methylene chloride, and the like. Compounds of formula 5 can be prepared by procedures described in working examples below.

- 25 Oxidation of the hydroxy group in (e) with a suitable oxidizing agent such as Oxone, Dess Martin Periodinane, TEMPO/bleach, and the like provides a compound of Formula (I).

Alternatively, a compound of Formula (I) can be prepared by proceeding as in the following Reaction Scheme 2 below.

Scheme 2




Reaction of a compound of formula (a), (f), or (g) with an amino compound of formula (h) provides a compound of formula (e) which is then converted to a compound of Formula (I) as described in Scheme 1 above. The reaction with the thione (f) is carried out in the presence of a suitable coupling agent such as 2-chloro-1-methylpyridinium iodide (Yong, Y. F., et. al., *J. Org. Chem.* 1997, 62, 1540), phosgene or triphosgene (Barton, D. H., et. al., *J. Chem. Soc. Perkin Trans. I*, 1982, 2085), alkyl halides (Brand, E and Brand, F. C., *Org. Synth.*, 1955, 3, 440), or carbodiimide (Poss, M. A., et. al., *Tet. Lett.*, 1992, 40, 5933).

The reaction with the imidate compound (g) is carried out optionally in the presence of a base such as triethylamine. Suitable reaction conditions are known to those skilled in the art and examples of such amine additions can be found in the art e.g., Haake, M., et. al., *Synthesis*, 1991, 9, 753; Dauwe, C., et al., *Synthesis*, 1995, 2, 171, Reid, et. al., *Justus Liebigs Ann. Chem.*, 1966, 97, 696; and Dean N. D., and Papadopoulos, E.P. *J. Het. Chem.*, 1982, 19, 1117.

Compounds (a), (f) and (g) are commercially available or they can be prepared by methods well known in the art. For example, *N*-phenyl-2,2,2-trifluorothioacetamide can be prepared by method described in *Tet. Lett.*, 2001, 42, 46, 8181-8184; *N*-thiazol-2-ylthioacetamide can be prepared by the procedure described in *Chem. Heterocyclo.*, 1972, 848-851; and *N*-thiazol-2-ylphenylthiobenzamide can be prepared as described in by the procedure described in *Chem. Heterocyclo.*, 1988, 337-344. Others can be prepared by methods are described in PCT Application Publication No. WO 02/20485 the disclosure of which is incorporated herein by reference in its entirety. Compounds of formula (g) are either commercially available or they can be prepared by methods known in the art. Some such methods are described in Francesconi, I., et. al., *J. Med. Chem.*, 1999, 42, 2260; Kurzer, F., et. al., *Org. Synth.* 1963, 645; and Futman, A. D., U. S Patent No. 3,984,410. For example, ethyl benzenesulfonyl formimidate can be prepared by methods described in Stetter, H. and Theisen, D. H. *Chem Ber.*, 1969, 102, 1641-42 and Ortiz, J. A., *Arzneim.-Forsch./Drug Res.*, 1977, 47, 431-434.

Compounds of formula (h) can be prepared by reacting an *N*-protected amino acid of formula (b) ($R' = H$) with a compound of formula (d) under the coupling reaction conditions described above, followed by removal of the amino protecting group. Suitable amino protecting groups include, but are not limited to, *tert*-butoxycarbonyl, benzyloxycarbonyl, and the like. Other methods that can be utilized for preparing compounds of Formula (I) are described in PCT Application Publication Nos. WO 02/20485 and WO 03/029200, and U.S. Patent 6,420,364, the disclosures of which are incorporated herein by reference in their entirety.

Alternatively, a compound of Formula (I) where R^4 is isopropylamine or cyclopentylamine and is attached to the amidine carbon atom via the nitrogen atom can be prepared by method disclosed in Scheme 3 below.



Reaction of a compound of formula (i) where LG is a leaving group, preferably methylthio, with a compound of formula (b) provides compound of formula (j). Reaction of the acid (j) with a compound of formula (d) under the reaction conditions described above provides a compound of formula (k). Reaction of (k) with isopropylamine or cyclopentylamine provides a compound of formula (l), which is then converted to a compound of Formula (I) as described above.

Pharmacology and Utility

The compounds of the invention are selective inhibitors of cysteine proteases, in particular, cathepsin S, and accordingly are useful for treating diseases in which cysteine protease activity contributes to the pathology and/or symptomatology of the disease. For example, the compounds of the invention are useful in treating autoimmune disorders, including, but not limited to, juvenile onset diabetes, psoriasis, multiple sclerosis, pemphigus vulgaris, Graves' disease, specifically

Grave's exophthalmos, myasthenia gravis, systemic lupus erythematosus, rheumatoid arthritis and Hashimoto's thyroiditis, allergic disorders, including, but not limited to, asthma, allogeneic immune responses, including, but not limited to, organ transplants or tissue grafts and endometriosis.

Cathepsin S is also implicated in disorders involving excessive elastolysis, such as chronic 5 obstructive pulmonary disease (e.g., emphysema), bronchiolitis, excessive airway elastolysis in asthma and bronchitis, pneumonitis and cardiovascular disease such as plaque rupture and atheroma. Cathepsin S is implicated in fibril formation and, therefore, inhibitors of cathepsins S are of use in treatment of systemic amyloidosis.

10 Preparation of Biological Agents

In practicing this invention several processes for the generation or purification of biological agents are used. Methods for preparing the biologics are well known in the art as discussed below.

Monoclonal antibodies are prepared using standard techniques, well known in the art, such as by the method of Kohler and Milstein, *Nature* 1975, 256:495, or a modification thereof, such as 15 described by Buck et al. 1982, *In Vitro* 18:377. Typically, a mouse or rat is immunized with the MenB PS derivative conjugated to a protein carrier, boosted and the spleen (and optionally several large lymph nodes) removed and dissociated into single cells. If desired, the spleen cells may be screened (after removal of non-specifically adherent cells) by applying a cell suspension to a plate or well coated with the antigen. B-cells, expressing membrane-bound immunoglobulin specific for 20 the antigen, will bind to the plate, and will not be rinsed away with the rest of the suspension. Resulting B-cells, or all dissociated spleen cells, are then induced to fuse with myeloma cells to form hybridomas. Representative murine myeloma lines for use in the hybridizations include those available from the American Type Culture Collection (ATCC).

Chimeric antibodies composed of human and non-human amino acid sequences may be 25 formed from the mouse monoclonal antibody molecules to reduce their immunogenicity in humans (Winter et al. *Nature* 1991 349:293; Lobuglio et al. *Proc. Nat. Acad. Sci. USA* 1989 86:4220; Shaw et al. *J. Immunol.* 1987 138:4534; and Brown et al. *Cancer Res.* 1987 47:3577; Riechmann et al. *Nature* 1988 332:323; Verhoeven et al. *Science* 1988 239:1534; and Jones et al. *Nature* 1986 321:522; EP Publication No.519,596, published Dec. 23, 1992; and U.K. Patent Publication No. GB 30 2,276,169, published Sep. 21, 1994).

Antibody molecule fragments, e.g., F(ab')_n.2, FV, and sFv molecules, that are capable of exhibiting immunological binding properties of the parent monoclonal antibody molecule can be produced using known techniques. Inbar et al. *Proc. Natl. Acad. Sci. USA* 1972 69:2659; Hochman et al. *Biochem.* 1976 15:2706; Ehrlich et al. *Biochem.* 1980 19:4091; Huston et al. *Proc. Natl. Acad. Sci. USA* 1988 85(16):5879; and U.S. Pat. Nos. 5,091,513 and 5,132,405, to Huston et al.; and U.S. Pat. No. 4,946,778, to Ladner et al.

In the alternative, a phage-display system can be used to expand the monoclonal antibody molecule populations *in vitro*. Saiki, et al. *Nature* 1986 324:163; Scharf et al. *Science* 1986 233:1076; U.S. Pat. Nos. 4,683,195 and 4,683,202; Yang et al. *J. Mol. Biol.* 1995 254:392; Barbas, III et al. *Methods: Comp. Meth Enzymol.* 1995 8:94; Barbas, III et al. *Proc. Natl. Acad. Sci. USA* 1991 88:7978.

The coding sequences for the heavy and light chain portions of the Fab molecules selected from the phage display library can be isolated or synthesized, and cloned into any suitable vector or replicon for expression. Any suitable expression system can be used, including, for example, bacterial, yeast, insect, amphibian and mammalian systems. Expression systems in bacteria include those described in Chang et al. *Nature* 1978 275:615, Goeddel et al. *Nature* 1979 281:544, Goeddel et al. *Nucleic Acids Res.* 1980 8:4057, European Application No. EP 36,776, U.S. Pat. No. 4,551,433, deBoer et al. *Proc. Natl. Acad. Sci. USA* 1983 80:21-25, and Siebenlist et al. *Cell* 1980 20:269.

Expression systems in yeast include those described in Hinnen et al. *Proc. Natl. Acad. Sci. USA* 1978 75:1929, Ito et al. *J. Bacteriol.* 1983 153:163, Kurtz et al. *Mol. Cell. Biol.* 1986 6:142, Kunze et al. *J. Basic Microbiol.* 1985 25:141, Gleeson et al. *J. Gen. Microbiol.* 1986 132:3459, Roggenkamp et al. *Mol. Gen. Genet.* 1986 202:302, Das et al. *J. Bacteriol.* 1984 158:1165, De Louvencourt et al. *J. Bacteriol.* 1983 154:737, Van den Berg et al. *Bio/Technology* 1990 8:135, Kunze et al. *J. Basic Microbiol.* 1985 25:141, Cregg et al. *Mol. Cell. Biol.* 1985 5:3376, U.S. Pat. Nos. 4,837,148 and 4,929,555, Beach et al. *Nature* 1981 300:706, Davidow et al. *Curr. Genet.* 1985 10:380, Gaillardin et al. *Curr. Genet.* 1985 10:49, Ballance et al. *Biochem. Biophys. Res. Commun.* 1983 112:284-289, Tilburn et al. *Gene* 1983 26:205-221, Yelton et al. *Proc. Natl. Acad. Sci. USA* 1984 81:1470-1474, Kelly et al. *EMBO J.* 1985 4:475479; European Application No. EP 244,234, and International Publication No. WO 91/00357.

- Expression of heterologous genes in insects can be accomplished as described in U.S. Pat. No. 4,745,051, European Application Nos. EP 127,839 and EP 155,476, Vlak et al. *J. Gen. Virol.* 1988 69:765-776, Miller et al. *Ann. Rev. Microbiol.* 1988 42:177, Carbonell et al. *Gene* 1988 73:409, Maeda et al. *Nature* 1985 315:592-594, Lebacq-Verheyden et al. *Mol. Cell. Biol.* 1988 8:3129, Smith et al. *Proc. Natl. Acad. Sci. USA* 1985 82:8404, Miyajima et al. *Gene* 1987 58:273, and Martin et al. *DNA* 1988 7:99. Numerous baculoviral strains and variants and corresponding permissive insect host cells from hosts are described in Luckow et al. *Bio/Technology* 1988 6:47-55, Miller et al. *GENERIC ENGINEERING*, Setlow, J. K. et al. eds., Vol. 8, Plenum Publishing, pp. 1986 277-279, and Maeda et al. *Nature* 1985 315:592-594.
- 10 Mammalian expression can be accomplished as described in Dijkema et al. *EMBO J.* 1985 4:761, Gorman et al. *Proc. Natl. Acad. Sci. USA* 1982 79:6777, Boshart et al. *Cell* 1985 41:521, and U.S. Pat. No. 4,399,216. Other features of mammalian expression can be facilitated as described in Ham et al. *Meth. Enz.* 1979 58:44, Barnes et al. *Anal. Biochem.* 1980 102:255, U.S. Pat. Nos. 4,767,704, 4,657,866, 4,927,762, 4,560,655 and Reissued U.S. Pat. No. RE 30,985, and in 15 International Publication Nos. WO 90/103430, WO 87/00195.
- The production of recombinant adenoviral vectors are described in U.S. Pat. No. 6,485,958.
- Botulinum toxin type A can be obtained by establishing and growing cultures of *Clostridium botulinum* in a fermenter and then harvesting and purifying the fermented mixture in accordance with known procedures.
- 20 Any of the above-described protein production methods can be used to provide the biologic that would benefit from the present invention.

Testing

- 25 The cysteine protease inhibitory activity, in particular, the Cathepsin S inhibitory activities of the compounds of the invention can be determined by methods known to those of ordinary skill in the art. Suitable *in vitro* assays for measuring protease activity and the inhibition thereof by test compounds are known. Typically, the assay measures protease-induced hydrolysis of a peptide-based substrate. Details of assays for measuring protease inhibitory activity are set forth in Biological Examples 1-6, *infra*.

30

Administration and Pharmaceutical Compositions

In general, a compound of the present invention will be administered in therapeutically effective amounts via any of the usual and acceptable modes known in the art, either singly or in combination with one or more therapeutic agents. A therapeutically effective amount may vary widely depending on the severity of the disease, the age and relative health of the subject, the 5 potency of the compound used and other factors. For example, therapeutically effective amounts of a compound or compounds of the present invention may range from about 10 micrograms per kilogram body weight ($\mu\text{g}/\text{kg}$) per day to about 20 milligram per kilogram body weight (mg/kg) per day, typically from about 100 $\mu\text{g}/\text{kg}/\text{day}$ to about 10 $\text{mg}/\text{kg}/\text{day}$. Therefore, a therapeutically effective amount for a 80 kg human patient may range from about 1 mg/day to about 1.6 g/day, 10 typically from about 1 mg/day to about 100 mg/day. In general, one of ordinary skill in the art, acting in reliance upon personal knowledge and the disclosure of this Application, will be able to ascertain a therapeutically effective amount of a compound of the present invention for treating a given disease.

The compounds of the present invention can be administered as pharmaceutical 15 compositions by one of the following routes: oral, systemic (e.g., transdermal, intranasal or by suppository) or parenteral (e.g., intramuscular, intravenous or subcutaneous). Compositions can take the form of tablets, pills, capsules, semisolids, powders, sustained release formulations, solutions, suspensions, elixirs, aerosols, or any other appropriate composition and are comprised of, in general, a compound of the present invention in combination with at least one pharmaceutically 20 acceptable excipient. Acceptable excipients are non-toxic, aid administration, and do not adversely affect the therapeutic benefit of the active ingredient. Such excipient may be any solid, liquid, semisolid or, in the case of an aerosol composition, gaseous excipient that is generally available to one of skill in the art.

Solid pharmaceutical excipients include starch, cellulose, talc, glucose, lactose, sucrose, 25 gelatin, malt, rice, flour, chalk, silica gel, magnesium stearate, sodium stearate, glycerol monostearate, sodium chloride, dried skim milk, and the like. Liquid and semisolid excipients may be selected from water, ethanol, glycerol, propylene glycol and various oils, including those of petroleum, animal, vegetable or synthetic origin (e.g., peanut oil, soybean oil, mineral oil, sesame oil, and the like). Preferred liquid carriers, particularly for injectable solutions, include water, 30 saline, aqueous dextrose and glycols.

The amount of a compound of the present invention in the composition may vary widely

depending upon the type of formulation, size of a unit dosage, kind of excipients and other factors known to those of skill in the art of pharmaceutical sciences. In general, a composition of a compound of the present invention for treating a given disease will comprise from 0.01%w to 10%w, preferably 0.3%w to 1%w, of active ingredient with the remainder being the excipient or 5 excipients. Preferably the pharmaceutical composition is administered in a single unit dosage form for continuous treatment or in a single unit dosage form ad libitum when relief of symptoms is specifically required. Representative pharmaceutical formulations containing a compound of the present invention are described in working examples below.


10

EXAMPLES

The present invention is further exemplified, but not limited by, the following examples that illustrate the preparation of compounds of Formula (I) according to the invention.

Reference A

15 Synthesis of 2(S)-(tert-butoxycarbonyl)amino-1-(oxazolo[4,5-*b*]pyridin-2-yl)butan-1-ol



Step 1

A mixture of 2-amino-3-hydroxypyridine (11 g, 100 mmol), triethylorthoformate (80 mL) 20 and p-toluenesulfonic acid (61 mg) was heated at 140 °C for 8 h. Excess triethylorthoformate was removed under vacuum and oxazolo[4,5-*b*]pyridine was crystallized from ethyl acetate (9 g).

Step 2


In a clean roundbottom flask equipped with stir bar was placed oxazolo[4,5-*b*]pyridine (600 mg, 5 mmol) in THF (30 mL) and the reaction mixture was cooled to 0 °C under N₂ atmosphere. 25 Isopropylmagnesium chloride (2 M in THF, 2.5 mL, 5 mmol) was added. After stirring for 1 h at 0 °C, (S)-2-(tert-butoxycarbonyl)aminobutyraldehyde (573 mg, 3 mmol) in THF (20 mL) was added. The ice bath was removed and the reaction mixture was allowed to warm to room temperature. After 2 h, the reaction mixture was quenched with saturated ammonium chloride solution and concentrated to dryness. The residue was extracted with EtOAc, then washed with brine, dried with

anhyd. MgSO₄, filtered and concentrated. The crude product was purified by chromatograph to yield 383 mg of the desired compound.

H¹ NMR (DMSO-d₆): δ 8.42 (m, 1H), 8.18 (m, 1H), 7.3(m, 1H), 6.8- 6.6 (dd, d, 1H, OH, diastereomer), 6.3- 6.02 (d, d, 1H, NH, diastereomer), 4.82- 4.5 (m,m, 1H, diastereomer), 1.8-1.3 (m, 2H), 1.2-1.05 (s,s, 9H, diastereomer), 0.89 (m, 3H). MS: 306.2 (M-1), 308.6 (M+1).

Reference B

Synthesis of (S)-2-amino-1-(3-phenyl-[1,2,4]oxadiazol-5-yl)-butan-1-ol



10


3-*tert*-Butoxycarbonylamino-2-hydroxy-pentanoic acid (500 mg, 2.14 mmol) was combined with EDC (600 mg, 3.14 mmol), HOBr (600 mg, 3.92 mmol), and *N*-hydroxy-benzamidine (292 mg, 2.14 mmol). Dichloromethane (10 mL) was added and then 4-methylmorpholine (1 mL). The reaction mixture was stirred at ambient temperature for 16 h. After dilution with ethyl acetate (200 mL), the solution was washed with water (30 mL), saturated aqueous NaHCO₃ solution and brine, dried with MgSO₄ and evaporated under vacuum. The crude product was dissolved in pyridine (10 mL) and heated at 80 °C for 15 h. The pyridine was evaporated under vacuum and the residue was purified by flash chromatography on silica gel (eluent: ethyl acetate) to yield (290mg, 0.83 mmol) of (S)-2-*tert*-butoxycarbonylamino-1-(3-phenyl-[1,2,4]oxadiazol-5-yl)-butan-1-ol. (S)-2-*tert*-butoxycarbonylamino-1-(3-phenyl-[1,2,4]oxadiazol-5-yl)-butan-1-ol (145 mg, 0.41mmol) was dissolved in CH₂Cl₂ (4 mL) and TFA (4 mL) was added. After stirring for 1 h, the reaction mixture was evaporated to dryness to yield (S)-2-amino-1-(3-phenyl-[1,2,4]oxadiazol-5-yl)-butan-1-ol.

20

Following the procedure described above but substituting *N*-hydroxypropamidine for *N*-hydroxy-benzamidine provided (S)-2-amino-1-(3-ethyl-[1,2,4]oxadiazol-5-yl)-butan-1-ol.

Reference C

Synthesis of (S)-2-amino-1-(2-methoxymethyl-[1,3,4]oxadiazol-5-yl)-butan-1-ol



Step 1

(*S*)-(+)-2-amino-1-butanol (50 g, 561 mmol) in a mixture of water and dioxane (200 mL of water and 200 mL dioxane) was cooled to 0 °C and mixed with NaOH (26.9 g, 673 mmol) and *tert*-butyl-dicarbonate (146.96 g, 673 mmol). After the addition, the reaction was allowed to warm to room temperature. The reaction mixture was stirred for 2 h. After removing the dioxane, the residue was extracted with EtOAc, then washed with brine and dried with anhydrous MgSO₄, filtered and concentrated. Without further purification, the crude (*S*-2-*Boc*-amino-1-butanol (120 g) was used for next step reaction.

Step 2

A solution of oxalyl chloride (40.39 g, 265 mmol) in MeCl₂ (700 mL) was stirred and cooled to -60 °C. Dimethylsulfoxide (51.7 g, 663 mmol) in MeCl₂ (100 mL) was added dropwise. After 10 min., a solution of (*S*)-2-*Boc*-amino-1-butanol (50 g, 265 mmol) in MeCl₂ (100 mL) was added dropwise at -70 °C. The reaction mixture was allowed to warm to -40 °C for 10 min. and then cooled to -70 °C again. A solution of triethylamine (74.9 g, 742 mmol) in MeCl₂ (100 mL) was added. The reaction mixture was allowed to warm to room temperature over 2 h. Saturated sodium dihydrogen phosphate (100 mL) was added, and then the organic layer was washed with brine and dried over MgSO₄. The solvent was removed to yield 45g of (*S*)-2-*Boc*-amino-butyraldehyde(1-formyl-propyl)-carbamic acid *tert*-butyl ester.

Step 3

A mixture of methyl methoxyacetate (52 g, 500 mmol), hydrazine hydrate (30 mL) was heated to reflux for 8 h. Excess hydrazine and water were removed under vacuum. The residue was extracted with n-butanol, dried with Na₂SO₄. Excess n-butanol was removed to yield 45g of hydrazide.

Step 4

A mixture of above hydrazide (45 g), triethylorthoformate (146 mL) and p-toluenesulfonic acid (61mg) was heated at 140 °C for 8 h. Excess triethylorthoformate was removed under vacuum. The product was purified by silica gel column chromatography to yield 4.6g of 2-methoxymethyl-1,3,4-oxadiazole.

Step 5

To a stirred solution of 2-methoxymethyl-1,3,4-oxadiazole (4.6 g, 40 mmol) in THF (100 mL) was added *n*-BuLi (1.6 M solution in 25.2 mL of hexane) dropwise under N₂ at -78 °C. After 1 h, MgBr.Et₂O (10.4 g, 40.3 mmol) was added and the reaction mixture was allowed to warm to -45 °C for 1 h before being treated with (*S*)-2-*Boc*-amino-propenylaldehyde butyraldehyde (5.28 g, 28.25 mmol) in THF (20 mL). The reaction mixture was stirred for 1 h, quenched with saturated NH₄Cl, and extracted with ethyl acetate. The organic layer was washed with brine, dried with MgSO₄ and concentrated. The residue was purified by silica gel column chromatography to yield (*S*)-2-*Boc*-amino-1-(5-methoxymethyl-[1,3,4]-oxadiazole-2-yl)-1-propanol butanol (500 mg).


10 Step 6

2-*Boc*-amino-1-(5-methoxymethyl-[1,3,4]-oxadiazole-2-yl)-1-propanol butanol (500 mg, 1.66 mmol), and MeCl₂ (5 mL) were mixed and TFA (0.5 mL) was added at room temperature. After stirring for 1 h, the solvent and excess TFA were removed under vacuum to produce (*S*)-2-amino-1-(5-methoxymethyl-[1,3,4]oxadiazol-2-yl)-butan-1-ol. TFA salt (340 mg).

15

Reference D

Synthesis of (*S*)-2-amino-1-(2-phenyl-[1,3,4]oxadiazol-5-yl)-1-butan-1-ol



20 Step 1

A mixture of the benzoic hydrazide (22.5 g, 165 mmol), triethylorthoformate (150 mL) and p-toluenesulfonic acid (300 mg) was heated at 120 °C for 12 h. Excess triethylorthoformate was removed under vacuum and the residue was purified by silica gel column chromatography to produce 2-phenyl-[1,3,4]-oxadiazole (14.5 g).

25 Step 2

To a stirred solution of the 2-phenyl-[1,3,4]oxadiazole (10 g, 68.5 mmol) in THF (100 mL) was added *n*-BuLi (1.6 M solution in 42.8 mL of hexane) dropwise under N₂ at -78 °C. After 1 h, MgBr.Et₂O (17.69 g, 68.5 mmol) was added and the reaction mixture was allowed to warm to -45 °C for 1 h before being treated with (*S*)-2-*Boc*-aminobutra-aldehyde (7.8 g, 41 mmol) in THF (20

mL). The reaction mixture was stirred for 1 h, quenched with saturated NH₄Cl, and extracted with ethyl acetate. The organic layer was washed with brine, dried with MgSO₄ and concentrated. The residue was purified by silica gel column chromatography to yield 2-((S)-2-Boc-amino-1-hydroxybutyl)-5-phenyl-[1,3,4]-oxadiazole (9.7 g).


5 Step 3

2-((S)-2-Boc-amino-1-hydroxybutyl)-5-phenyl-[1,3,4]-oxadiazole (505 mg, 1.5 mmol) and MeCl₂ (5 mL) were mixed and TFA (1 mL) was added at room temperature. After stirring for 1 h, the solvent and excess TFA were removed under vacuum to produce 530 mg of (S)-2-amino-1-(5-phenyl-[1,3,4]oxadiazol-2-yl)-1-butanol TFA salt.

10

Reference E

Synthesis of (S)-2-amino-1-oxazolo[4,5-b]pyridin-2-yl-butan-1-ol



15 Step 1

A mixture of 2-amino-3-hydroxypyridine (25 g, 227 mmol), triethylorthoformate (75 mL) and p-toluenesulfonic acid (61 mg) was heated at 140 °C for 8 h. Excess triethylorthoformate was removed under vacuum. The product was crystallized from ethyl acetate to yield 22.5 g of oxazolo[4,5-b]pyridine.

20 Step 2

To a stirred solution of the oxazolo[4,5-b]pyridine (12 g, 100 mmol) in THF (300 mL) was added n-BuLi (1.6 M solution in 62.5 mL of hexane) drop wise under N₂ at -78 °C. After 1 h, MgBr.Et₂O (25.8 g, 100 mmol) was added and the reaction mixture was allowed to warm to -45 °C for 1 h before being treated with (S)-2-Boc-amino-butylaldehyde (11.46 g, 60 mmol) in THF (50 mL). The reaction mixture was stirred for 1 h, quenched with saturated NH₄Cl, and extracted with ethyl acetate. The organic layer was washed with brine, dried with MgSO₄ and concentrated. The residue was purified by silica gel column chromatography to yield (S)-2-Boc-amino-1-(oxazolo[4,5-b]pyridin-2-yl)-1-butanol (14.1 g).

25 Step 3


30 (S)-2-Boc-amino-1-(oxazolo[4,5-b]pyridin-2-yl)-1-butanol (311 mg, 1 mmol) and MeCl₂

(5mL) were mixed and TFA (1mL) was added at room temperature. After stirring for 1 h, the solvent and excess TFA were removed under vacuum to produce 355 mg of (*S*)-2-amino-1-oxazolo[4,5-*b*]pyridin-2-yl-butan-1-ol. TFA salt.

5

Reference F

Synthesis of (*S*)-2-amino-1-benzoxazol-2-ylbutan-1-ol hydrochloride



Step 1

To a solution of benzoxazole (28.6 g, 240 mmol) in toluene (150 mL) was added during ca 10 20 min., at about -4 °C a 2 M solution of isopropyl-magnesium chloride in THF (120 mL, 240 mmol). The red-brown mixture was stored at ca -4°C and used as needed.

Step 2

To a solution of (*S*)-2-*Boc*-aminobutanol (50 g; 264 mmol) in dichloromethane (500 mL) and water (350 mL) were added at 20° C TEMPO (0.01 eq), sodium bromide (1 eq) and sodium 15 hydrogencarbonate (3 eq). The reaction mixture was stirred at 0° C and diluted bleach (1.3 eq, 450 mL) was added over 40 min. The reaction mixture was stirred for 30 min. at 0° C and then quenched with aq. thiosulfate. After decantation and extractions (dichloromethane), the organic phase was washed with brine, dried and concentrated *in vacuo* to dryness, giving (*S*)-2-(*tert*-butoxycarbonyl)-aminobutyraldehyde as a low-melting solid (38.1 g; yield: 77%).

Step 3


A solution of (*S*)-2-(*tert*-butoxycarbonyl)amino-butyr aldehyde (30 g, 160 mmol) in toluene (150 mL) was added over 30 min. at -5 ° C to a solution of Grignard reagent of benzoxazole (prepared as described in Step 1 above). The reaction mixture was stirred for 0.5 h at 0° C, then 2.5 h at RT. Quenching with 5% aq. acetic acid, washings with 5% aq. sodium carbonate, then brine 25 and concentration to dryness gave crude (*S*)-2-(*tert*-butoxycarbonyl)-amino-1-benzoxazol-2-ylbutan-1-ol. The residue was diluted with toluene, and silica gel was added. The slurry was filtered. Elution by toluene removed the non-polar impurities. Then an 8/2 mixture of toluene and ethyl acetate desorbed the (*S*)-2-(*tert*-butoxycarbonyl) amino-1-benzoxazol-2-ylbutan-1-ol.

Step 4

To a solution of (*S*)-2-(*tert*-butoxycarbonyl)amino-1-benzoxazol-2-yl-propan-1-ol (26.3 g, 86 mmol) in isopropanol (118 mL) at 20–25 °C was added trimethylchlorosilane (1.4 eq). The solution was stirred for 5 h at 50°C. Concentration of the reaction mixture to 52 mL followed by addition of isopropyl ether (210 mL), filtration and drying under vacuum afforded (*S*)-2-amino-1-benzoxazol-2-ylbutan-1-ol hydrochloride salt as a grey solid (16.4 g; yield = 79 %; mixture of diastereomers).

Reference G

- 10 Synthesis of {1-[{(2-ethyl-[1,3,4]oxadiazol-2-yl)hydroxymethyl]propyl}carbamic acid *tert*-butyl ester



Step 1


- 15 A mixture of the formic hydrazide (60 g, 1 mole), triethylorthopropionate (176.26 g, 1 mole) and *p*-toluenesulfonic acid (250 mg) was heated at 120°C for 12 hours. The ethanol was removed under vacuum and the residue was distilled under vacuum to yield 24g of ethyl-1,3,4-oxadiazole.

Step 2

- 20 To a stirred solution of the ethyl-1,3,4-oxadiazole (4.66 g, 48 mmol) in THF (50 mL) was added *n*-BuLi (1.6M solution in 30 mL of hexane) drop-wise under N₂ at -78°C. After 1 hour, MgBr-Et₂O (12.38 g, 48 mmol) was added and the reaction mixture was allowed to warm to -45°C for 1 hour before being treated with 2-Boc-Nlu-aldehyde (3.2 g, 24 mmol) in THF (20 mL). The reaction mixture was stirred for 1 hour, quenched with saturated NH₄Cl, and extracted with ethyl acetate. The organic layer was washed with brine, dried with MgSO₄ and concentrated. The residue was purified by silica gel column chromatography to yield {1-[{(2-ethyl-[1,3,4]oxadiazol-5-yl)hydroxymethyl]propyl}carbamic acid *tert*-butyl ester (2.13g). ¹ NMR (DMSO-δ): 6.65–6.52 (1H, d, d, J=9.2Hz, J=9.2Hz, NH, diastereomer), 6.14, 5.95 (1H, d, d, J=5.6Hz, J=5.6Hz, OH, diastereomer), 4.758–4.467 (1H, m, diastereomer), 3.7–3.55 (1H, m), 2.8 (2H, q), 1.33(12H, t), 1.25–1.21 (2H, m), 0.82 (3H, m). MS: 284.1 (M-1), 286 (M+1), 308 (M+Na).

Reference H

Synthesis of thiophene-2-carbothioic acid (2,2,2-trifluoroethyl)amide



5 Step 1

Thiophene-2-carboxylic acid was coupled to trifluoroethyl amine using HBTU utilizing a procedure described in Example 1, Step 2 below except substituting HOBr with HBTU to give thiophene-2-carboxylic acid (2,2,2-trifluoroethyl)amide.

Step 2

10 To thiophene-2-carboxylic acid (2,2,2-trifluoroethyl)amide (2.8 g, 13.28 mmol, 1.0 equiv.) in toluene (100 mL) was added Lawesson's reagent (2.71 g, 6.69 mmol, 0.5 equiv.). The solution was stirred at 100 °C for 3 h. The solvent was removed in vacuo and the resulting residue was purified by flash chromatography (5% EtOAc/hexanes as eluent) to afford the title compound (1.4 g) as a yellow solid. MS = 225.9 (M + 1).

15 Proceeding as described above, but substituting thiophene-2-carboxylic acid with commercially available starting materials, the following compounds were prepared:

Phenyl-2-carbothioic acid (2,2,2-trifluoroethyl)amide; MS = 220 (M + 1)


4-Fluorophenylcarbothioic acid (2,2,2-trifluoroethyl)amide; MS = 238 (M + 1); and

Tetrahydropyran-4-carbothioic acid (2,2,2-trifluoroethyl)-amide; MS = 225.8 (M - 1).

20

Reference I

Synthesis of 1,1-dioxo-1,2-dihydro-1λ⁶-thieno[2,3-d]isothiazol-3-one



Step 1

25 Methyl 4-(chlorosulfonyl)thiophene-3-carboxylate (5 g, 20.75 mmol) was dissolved in

methylene chloride (50 mL), the solution was cooled to 0 °C, and ammonia gas (1.1 g, 64.7 mmol) was introduced during 20 min. After a further 2 h of stirring, the reaction mixture was washed to neutrality with 10% aqueous hydrochloric acid and then with brine. After concentration os the solvent, crude methyl 4-sulfamoylthiophene-3-carboxylate was obtained which was recrystallized
5 from ethanol to yield 2.7g of methyl 4-sulfamoylthiophene-3-carboxylate. MS: 220 (M-1), 221.9 (M+1), 243.8 (M+Na).


Step 2

A mixture of methyl 4-sulfamoylthiophene-3-carboxylate (2.7 g, 12.2 mmol), methanol (12 mL), and a 25% methanolic solution of sodium methylate (3.6 mL) was refluxed for 48 h. The
10 reaction mixture was cooled to room temperature and acidified with concentrated hydrochloride acid, and the precipitated product was collected and washed with water. Recrystallized from water, yielded 400mg of the title compound. MS: 187.8 (M-1), 189.5 (M+1). ¹H NMR(DMSO-d₆): 8.34 (d, J=4.4Hz, 1H), 7.705 (d, J=4.8Hz, 1H).

15

Reference J

Synthesis of 1-cyclopentyl-3-methylsulfonylthiourea




20 To methylsulfonyl isothiocyanate (175 mg, 0.128 mmol, 1.0 equiv.) (prepared according to a literature procedure described in *J. Org. Chem.* 1967, p 340) in benzene (1 mL) was added cyclopentyl amine (130 mg, 1.53 mmol 1.2 equiv.) and the mixture was heated to 80 °C in a microwave instrument. Upon cooling, 1-cyclopentyl-3-methylsulfonylthiourea precipitated as brown needles and was filtered (210 mg).

25

Reference K

Synthesis of (*R*)-2-*tert*-butoxycarbonylamino-3-cyclopropylmethanesulfonylpropionic acid



Step 1

Sodium hydroxide (2.16 g, 54 mmol) was dissolved in water (27 mL) and the solution added to a suspension of (*R*)-2-*tert*-butoxycarbonylamino-3-mercaptopropionic acid (8.2 g, 37 mmol) in 5 methanol (54 mL). After a clear solution had formed bromomethyl-cyclopropane (5 g, 37 mmol) was added and the resulting reaction mixture stirred for three days. Methanol was removed under reduced pressure. The residue was treated with 1M hydrochloric acid (200 mL) and then extracted with dichloromethane. The combined organic phases were washed with brine and dried with magnesium sulfate. The solvent was evaporated under reduced pressure to give 2-*tert*-butoxycarbonylamino-3-cyclopropylmethylsulfanyl-propionic acid (7.94 g).


Step 2

Sodium hydroxide (2.32 g, 58 mmol) was dissolved in water (27 mL). 2-*tert*-Butoxycarbonylamino-3-cyclopropylmethylsulfanyl-propionic acid (7.94 g, 29 mmol) was added. A solution of Oxone™ in water (100 mL) was added slowly. The pH was adjusted to 3 by addition 15 of sodium bicarbonate and the reaction mixture stirred for 30 minutes and extracted with ethyl acetate. The combined organic phases were washed with brine and dried with magnesium sulfate. The solvent was removed to yield (*R*)-2-*tert*-butoxycarbonylamino-3-cyclopropylmethanesulfonyl-propionic acid (4.64 g, 15 mmol, 31%).

20

Reference L

Synthesis of 2(*S*)-amino-N-[1(*S*)-(benzoxazol-2-ylhydroxymethyl)propyl]-3-(1-methylcyclopentyl)propionamide



Step 1

1-Methylcyclopentanol (20 g, 0.2 mol) was added to hydrobromic acid (40 mL) at room temperature. After stirring for 1h, the solution was extracted with hexane and the hexane was washed with brine and dried with magnesium sulfate. After concentration of the organic layer, 20.5 g of 1-methylcyclopentyl bromide was obtained.

5 Step 2

Tributyltin hydride (37.8 g, 130 mmol) was added at reflux to a 500 ml of flask charged with benzene (200 mL) was added Z-dehydro-Ala-OH (15 g, 64 mmol), 1-methylcyclopentylbromide (20.5 g) and AIBN (1.9g). After 2 h, the solvent was removed and the residue was purified by column chromatograph to yield 7.9g of 2-benzyloxycarbonylamino-3-(1-methylcyclopentyl)-

10 propionic acid methyl ester.

Step 3

2-Benzylloxycarbonylamino-3-(1-methylcyclopentyl)-propionic acid methyl ester (7.6 g, 23.8 mmol) was dissolved in a mixture of acetonitrile (82 mL) and 0.2 M aqueous NaHCO₃ (158 mL) and Alcalase 2.4L (1.1mL) was added and the reaction mixture wa stirred vigorously for 8 h.

15 The reaction mixture was then evaporated at 30 °C to remove acetonitrile, and the aqueous residue was washed with ether. The ethereal layer was concentrated to yield 1.9g of (R)-2-benzylloxycarbonylamino-3-(1-methylcyclopentyl)-propionic acid methyl ester. The aqueous phase was filtered with Celite, the pH was adjusted to 3 with 6 N HCl, and the solution was extracted with ethylacetate. The ethyl acetate layer was dried and evaporated to yield 1.4g of (S)-2-benzylloxycarbonylamino-3-(1-methyl-cyclopentyl)-propionic acid.

20 Step 4

To a stirred mixture of (S)-2-benzylloxycarbonylamino-3-(1-methylcyclopentyl)-propionic acid (560 mg, 1.84 mmol), 2-amino-1-benzoxazol-2-ylbutan-1-ol (378 mg, 1.84 mmol), and HOBr (338 mg, 2.2 mmol) in MeCl₂ (10mL) were added EDC (533 mg, 2.76 mmol) and N-methylmorpholine (373 mg) at room temperature. After stirring for 14 h, the reaction mixture was extracted with ethyl acetate. The organic layer was washed with saturated NaHCO₃, brine, dried with MgSO₄ and concentrated. Purification with column chromatograph yielded 600 mg of [1-[1(S)-(benzoxazol-2-ylhydroxymethyl)propyl-carbamoyl]-2(S)-(1-methylcyclopentyl)ethyl]-carbamic acid benzyl ester.

25 Step 5


Pd/C (5%) (60 mg) was added to a solution of of [1-[1-(benzoxazol-2-ylhydroxy-

methyl)propylcarbamoyl]-2-(1-methylcyclopentyl)ethyl]-carbamic acid benzyl ester (600 mg) in EtOH (30 mL) and the reaction mixture was stirred under hydrogen atmosphere (50 psi) for 2 h. The catalyst was removed by filtration and the filtrate was concentrated to yield 430 mg of the title compound. MS: 358.2 (M-1). 360.1 (M+1), 382.0(M+Na).

5

Example 1

Synthesis of 2-(1,1-dioxo-2,3-dihydro-1*H*-λ⁶-benzo[d]isothiazol-3-yl)-*N*-(1-(3-ethyl-[1,2,4]oxadiazol-5-ylcarbonyl)propyl)-3-(1-methylcyclopentyl)propionamide



10

Step 1

(S)-2-Amino-3-cyclopentyl-3-methylpropionic acid hydrobromide (1 g, 3.97 mmol) was dissolved in 1 N aqu. sodium hydroxide (10 mL) and dioxane (5 mL) and cooled in an ice bath, 3-chlorobenzo[d]isothiazole-1,1-dioxide (0.804 g, 4 mmol), prepared by the procedure described in David, F. A., *J. Org. Chem.*, 1990, 55, 1254, was added. The reaction mixture was allowed to warm to room temperature and then acidified with 1 N HCl and the product was isolated with ethyl acetate. Crystallization from ethyl acetate -hexane gave (S)-3-cyclopentyl-2-(1,1-dioxo-benzo[d]isothiazol-3-ylamino)-3-methylpropionic acid (1.5 g).

Step 2


A mixture of (S)-3-cyclopentyl-2-(1,1-dioxobenzo[d]isothiazol-3-ylamino)-3-methylpropionic acid (0.168 g, 0.5 mmol), (S)-2-amino-(3-ethyl-[1,2,4]oxadiazol-5-yl)butanol (0.093 g, 0.5 mmol), HOEt (0.092 g, 0.6 mmol), EDC (0.145 g, 0.75 mmol), NMM (0.202 g, 2 mmol), and methylene chloride (5 mL) was stirred at room temperature. The product was isolated by dilution of the reaction mixture with water and extraction with ethyl acetate to give 2-(1,1-dioxo-2,3-dihydro-1*H*-λ⁶-benzo[d]isothiazol-3-yl)-*N*-(1-[(3-ethyl-[1,2,4]oxadiazol-5-yl)-hydroxymethyl]propyl)-3-(1-methylcyclopentyl)propionamide.

Step 3

A solution of -(1,1-dioxo-2,3-dihydro-1*H*-λ⁵-benzo[d]isothiazol-3-yl)-*N*-{1-[(3-ethyl-[1,2,4]oxadiazol-5-yl)-hydroxy-methyl]propyl}-3-(1-methylcyclopentyl)propionamide (0.25 g, 0.5 mmol) in methylene chloride (5 mL) was treated with Dess-Martin periodinane (0.254 g, 0.6 mmol) at room temperature. The reaction was followed by HPLC. The reaction mixture was quenched 5 with aq. sodium thiosulfate. Water-ethyl acetate work up, followed by column chromatography gave the title compound (0.049 g). M. P. 202-204 °C. MS 500.4 (M-1) and 502.2 (M+1).

Example 2

Synthesis of *N*-[1-(benzoxazol-2-ylcarbonyl)propyl]-3-cyclohexyl-2-[(methanesulfonylimino-pyrrolidin-1-ylmethyl)amino]propionamide
10



Step 1

Using the method of (H.G. McFadden, J.L. Huppatt and P. K. Halladay, *Aust. J. Chem.*, 15 1993, 46, 873-886) and substituting methane sulfonamide for 2-chlorobenzenesulfonamide gave *N*-[bis(methylthio)methylene]-methanesulfonamide.

Step 2

N-[bis(methylthio)methylene]-methanesulfonamide (400 mg, 2 mmol) was dissolved in water (4 mL). 1N NaOH (4mL, 4 mmol) was added to the reaction mixture was stirred at 70 °C for 12 20 hours. Water (30 mL) was added to the reaction mixture and then extracted with ethyl ether. The aqueous layer was acidified with 1N HCl to pH 4. The product was extracted with ethyl acetate and the organic extracts were combined and dried over anhydrous magnesium sulfate, filtered and concentrated to afford 3-cyclohexyl-2-[(methanesulfonyliminomethylsulfanyl)methyl]amino]-propionic acid (664mg) as a colorless oil. 3-Cyclohexyl-2-[(methanesulfonyliminomethylsulfanyl-methyl)amino]-propionic acid was reacted with 2-amino-3-cyclohexylpropionic acid [1-(benzoxazol-2-ylhydroxymethyl)-propyl]amide to give *N*-[1-(benzoxazol-2-ylhydroxymethyl)-propyl]-3-cyclohexyl-2-[(methanesulfonylimino-methylsulfanyl)methyl]amino]propionamide.


Step 3

A solution of *N*-[1-(benzoxazol-2-ylhydroxymethyl)-propyl]-3-cyclohexyl-2-

[(methanesulfonylimino-methylsulfanyl)methyl]amino]propionamide (254 mg, 0.5 mmol) and pyrrolidine (0.25 M) was added in a 5 mL microwave vial was heated in a microwave (Optimizer) at 89 °C for 1h. The excess solvent was then removed by rotary evaporation, and the crude product was purified by silica gel chromatography (eluted with EtOAc/Hexane, 5:1) to afford *N*-[1-(benzoxazol-2-ylhydroxymethyl)propyl]-3-cyclohexyl-2-[(methanesulfonyliminopyrrolidin-1-yl-methyl)amino]propionamide (234 mg) as white solid. *N*-[1-(Benzoxazol-2-ylhydroxymethyl)-propyl]-3-cyclohexyl-2-[(methanesulfonyliminopyrrolidin-1-yl-methyl)amino]propionamide was converted to the title compound as described in Example 1, step 3 above.

Example 3

Synthesis of ($\{1-[1-(\text{benzoxazol-2-ylcarbonyl})\text{propylcarbamoyl}\}-2\text{-cylohexylethylamino}\}-\text{phenylmethylene}\})\text{carbamic acid ethyl ester}$



Step 1

A mixture of *N*-Boc-cyclohexyl alanine (1.8 g, 6.58 mmol), (*S*)-2-amino-1-benzoxazol-2-ylbutan-1-ol (1.6 g, 6.58 mmol), EDC (1.65 g, 8.5 mmol), HOBr (1.21 g, 7.9 mmol), NMM (1.42 mL) and methylene chloride was stirred at room temperature for 2 hours. The reaction mixture was

then diluted with methylene chloride and washed with water, aqueous sodium bicarbonate and then brine. Evaporation of the solvent then gave 2-*N*-tert-butoxycarbonylamino-3-cyclohexylpropionic acid [1(*S*)-(benzoxazol-2-ylhydroxymethyl)propyl]-amide (2.3 g). This product was dissolved in 4N HCl in dioxane (5 mL). After stirring at room temperature for 2 hours the solvent and excess HCl were removed by evaporation and the residue was dissolved in water and freeze dried to give 2-amino-3-cyclohexylpropionic acid [1(*S*)-(benzoxazol-2-ylhydroxymethyl)propyl]-amide (1.5 g).

Step 2

To a solution of N-ethoxycarbonylbenzene thiamide (27 mg, 0.13 mmol) (prepared by the procedure described in Papadonopoulos, E. P., J. Org. Chem., 1976, 41, 962) and (50 mg, 0.13 mmol) in methylene chloride was added 2-chloro-1-methylpyridinium iodide (41 mg, 0.16 mmol) and

NMM (39 mg, 0.39 mmol). The reaction mixture was stirred at room temperature overnight. After diluting the reaction mixture with water, the methylene chloride layer was separated and washed with sat. aq. sodium bicarbonate and brine. After concentration, the crude product was purified by column chromatography (1:1 ethyl acetate: hexane) to give ({1-[1-(benzoxazol-2-
 5 ylhydroxymethyl)propylcarbamoyl]-2-cyclohexyl-ethylamino}phenylmethylene)carbamic acid ethyl ester which was converted to the title compound as described in Example 1, Step 3 above.

The analytical data for some of the compounds of this invention and their method of synthesis are as follows:

Cpd. #	LC/MS peaks	Method of Synthesis
1	536.5 (M+H), 534.3 (M-H)	Example 1
2	509.2 (M+H), 507.1 (M-H)	Example 1
3	661.6 (M+H)	
4	550(M+1), 548(M-1), 572(M+23)	Example 1
5	537(M+1), 535(M-1), 559(M+23)	Example 1
6	523.4(M+1), 521.5(M-1)	
9	502.2(M+1), 500.4(M-1)	
10	524.2(M+1), 522.4(M-1)	
11	550.2(M+1), 548.2(M-1)	
12	502.2 (M+1), 500.3 (M-1)	
15	584.4 (M+1), 582.4 (M-1)	Example 2
16	532.3 (M+1), 530.3 (M-1)	Example 2
17	520.5 (M+1), 518.4 (M-1)	Example 2
18	546.5 (M+1), 544.3 (M-1)	Example 2
19	548.1 (M+1), 546.1 (M-1)	Example 2
20	488.1 (M+1), 486 (M-1)	Example 1
27	551.3 (M+1), 549.3 (M-1)	Example 1
32	550.1(M+1), 548.2(M-1)	
33	551.4(M+1), 549.3(M-1),	
34	538.3(M+1), 536.2(M-1),	
35	524(M+1), 522(M-1), 546(M+23)	Example 1
36	502(M+1), 500(M-1), 524(M+23)	Example 1
37	502(M+1), 500(M-1), 524(M+23)	Example 1
38	533(M+1), 531(M-1), 555(M+23)	Example 3
39	569(M+1), 567(M-1), 591(M+23)	Example 3
40	579(M+1), 577(M-1), 601(M+23)	Example 3
41	597(M+1), 595(M-1), 619(M+23)	Example 3
42	502(M+1), 500(M-1), 524(M+23)	Example 1
50	551.6 (M+H)	
51	556.5 (M+H)	

Cpd. #	LC/MS peaks	Method of Synthesis
52	518.5 (M+H)	
53	581.7 (M+H)	
54	538.3 (M+H)	
55	678.4 (M+H)	
56	615.4 (M+H)	

Biological Assays

5

Example 1

Cathepsin B Assay

Solutions of test compounds in varying concentrations were prepared in 10 μL of dimethyl sulfoxide (DMSO) and then diluted into assay buffer (40 μL , comprising: *N,N*-bis(2-hydroxyethyl)-2-aminoethanesulfonic acid (BES), 50 mM (pH 6); polyoxyethylene sorbitan monolaurate, 0.05%; 10 and dithiothreitol (DTT), 2.5 mM). Human cathepsin B (0.025 pMoles in 25 μL of assay buffer) was added to the dilutions. The assay solutions were mixed for 5-10 seconds on a shaker plate, covered and incubated for 30 minutes at room temperature. Z-FR-AMC (20 nMoles in 25 μL of assay buffer) was added to the assay solutions and hydrolysis was followed spectrophotometrically at (λ 460 nm) for 5 minutes. Apparent inhibition constants (K_i) were calculated from the enzyme 15 progress curves using standard mathematical models.

Compounds of the invention were tested by the above-described assay and observed to exhibit cathepsin B inhibitory activity.

Example 2

20

Cathepsin K Assay

Solutions of test compounds in varying concentrations were prepared in 10 μL of dimethyl sulfoxide (DMSO) and then diluted into assay buffer (40 μL , comprising: MES, 50 mM (pH 5.5); EDTA, 2.5 mM; and DTT, 2.5 mM). Human cathepsin K (0.0906 pMoles in 25 μL of assay buffer) was added to the dilutions. The assay solutions were mixed for 5-10 seconds on a shaker plate, 25 covered and incubated for 30 minutes at room temperature. Z-Phe-Arg-AMC (4 nMoles in 25 μL of assay buffer) was added to the assay solutions and hydrolysis was followed spectrophotometrically at (λ 460 nm) for 5 minutes. Apparent inhibition constants (K_i) were

calculated from the enzyme progress curves using standard mathematical models.

Compounds of the invention were tested by the above-described assay and observed to exhibit cathepsin K inhibitory activity.

5

Example 3
Cathepsin L Assay

Solutions of test compounds in varying concentrations were prepared in 10 μ L of dimethyl sulfoxide (DMSO) and then diluted into assay buffer (40 μ L, comprising: MES, 50 mM (pH 5.5); EDTA, 2.5 mM; and DTT, 2.5 mM). Human cathepsin L (0.05 pMoles in 25 μ L of assay buffer) was added to the dilutions. The assay solutions were mixed for 5-10 seconds on a shaker plate, covered and incubated for 30 minutes at room temperature. Z-Phe-Arg-AMC (1 nMoles in 25 μ L of assay buffer) was added to the assay solutions and hydrolysis was followed spectrophotometrically at (λ 460 nm) for 5 minutes. Apparent inhibition constants (K_i) were calculated from the enzyme progress curves using standard mathematical models.

10 15 Compounds of the invention were tested by the above-described assay and observed to exhibit cathepsin L inhibitory activity.

Example 4
Cathepsin S Assay

20 Solutions of test compounds in varying concentrations were prepared in 10 μ L of dimethyl sulfoxide (DMSO) and then diluted into assay buffer (40 μ L, comprising: MES, 50 mM (pH 6.5); EDTA, 2.5 mM; and NaCl, 100 mM); β -mercaptoethanol, 2.5 mM; and BSA, 0.00%. Human cathepsin S (0.05 pMoles in 25 μ L of assay buffer) was added to the dilutions. The assay solutions were mixed for 5-10 seconds on a shaker plate, covered and incubated for 30 minutes at room 25 temperature. Z-Val-Val-Arg-AMC (4 nMoles in 25 μ L of assay buffer containing 10% DMSO) was added to the assay solutions and hydrolysis was followed spectrophotometrically (at λ 460 nm) for 5 minutes. Apparent inhibition constants (K_i) were calculated from the enzyme progress curves using standard mathematical models.

30 Compounds of the invention were tested by the above-described assay and observed to exhibit cathepsin S inhibitory activity.

Example 5
Cathepsin F Assay

- Solutions of test compounds in varying concentrations were prepared in 10 μ L of dimethyl sulfoxide (DMSO) and then diluted into assay buffer (40 μ L, comprising: MES, 50 mM (pH 6.5); 5 EDTA, 2.5 mM; and NaCl, 100 mM); DTT, 2.5 mM; and BSA, 0.01%. Human cathepsin F (0.1 pMoles in 25 μ L of assay buffer) was added to the dilutions. The assay solutions were mixed for 5-10 seconds on a shaker plate, covered and incubated for 30 minutes at room temperature. Z-Phe-Arg-AMC (2 nMoles in 25 μ L of assay buffer containing 10% DMSO) was added to the assay 10 solutions and hydrolysis was followed spectrophotometrically (at λ 460 nm) for 5 minutes.
- 10 Apparent inhibition constants (K_i) were calculated from the enzyme progress curves using standard mathematical models.

Compounds of the invention were tested by the above-described assay and observed to exhibit cathepsin F inhibitory activity.

15 Example 6

In vitro Lip10 accumulation assay

- During normal antigen presentation, Lip10 is proteolytically degraded to enable loading of a peptide fragment and subsequent MHC-II presentation on the surface of antigen presenting cells.
- 20 The cleavage process is mediated by Cathepsin S. Thus, the Lip10 assay is an *in vitro* measure of a compound's ability to block cathepsin S and by extension antigen presentation. A compound that causes the accumulation of Lip10 at low concentration would be expected to block presentation of antigens.
- Method:
- 25 Raji cells (4×10^6) were cultured with 0.02% DMSO or different concentrations of Cathepsin S inhibitors in RPMI medium 1640 containing 10 % (v/v) FBS, 10 mM HEPES, 2 mM L-glutamine, and 1 mM sodium pyruvate for four hours at 37°C in 5% CO₂ humidified atmosphere.
- After the culture period, cells were washed with cold PBS and cells were then lysed in NP-40 lysis buffer (5 mM EDTA, 1% NP-40, 150 mM NaCl, and 50 mM Tris, pH 7.6) with protease inhibitors.
- 30 Protein determinations were performed and lysate samples were boiled in reducing SDS sample buffer. Proteins were separated by electrophoresis on 12% NuPAGE® Bis-Tris gels. Proteins were then transferred to nitrocellulose membranes, and after incubation with blocking buffer (5% non-fat

dry milk in PBS-Tween), the blots were incubated with the primary antibody against human CD74 invariant chain synthetic peptide (1.5 to 2 µg/ml of mouse anti-CD74 monoclonal antibody, PIN.1, Stressgen Biotechnologies). Blots were then incubated with the secondary antibody, horseradish peroxidase conjugated donkey anti-mouse IgG, at a 1:10,000 dilution. Immunoreactive proteins 5 were detected by chemiluminescence reaction using Pierce Super Signal® West Pico chemiluminescence substrate.

Pharmaceutical Composition Examples

10 The following are representative pharmaceutical formulations containing a compound of the present invention.

Tablet Formulation

15 The following ingredients are mixed intimately and pressed into single scored tablets.

	Ingredient	Quantity per tablet, mg
	compound of this invention	400
	cornstarch	50
20	croscarmellose sodium	25
	lactose	120
	magnesium stearate	5

Capsule Formulation

25 The following ingredients are mixed intimately and loaded into a hard-shell gelatin capsule.

	Ingredient	Quantity per capsule, mg
	compound of this invention	200
30	lactose, spray-dried	148
	magnesium stearate	2

Suspension Formulation

35 The following ingredients are mixed to form a suspension for oral administration.

	Ingredient	Amount
	compound of this invention	1.0 g
	fumaric acid	0.5 g
	sodium chloride	2.0 g
40	methyl paraben	0.15 g
	propyl paraben	0.05 g
	granulated sugar	25.5 g
	sorbitol (70% solution)	12.85 g

Veegum K (Vanderbilt Co.)	1.0 g
flavoring	0.035 mL
colorings	0.5 mg
distilled water	q.s. to 100 mL

5

Injectable Formulation

The following ingredients are mixed to form an injectable formulation.

Ingredient	Amount
compound of this invention	1.2 g
sodium acetate buffer solution,	0.4 M 2.0 mL
HCl (1 N) or NaOH (1 N)	q.s. to suitable pH
water (distilled, sterile)	q.s.to 20 mL

15 All of the above ingredients, except water, are combined and heated to 60-70 °C with stirring. A sufficient quantity of water at 60 °C is then added with vigorous stirring to emulsify the ingredients, and water then added q.s. to 100 g.

Suppository Formulation


20 A suppository of total weight 2.5 g is prepared by mixing the compound of the invention with Witepsol® H-15 (triglycerides of saturated vegetable fatty acid; Riches-Nelson, Inc., New York), and has the following composition:

compound of the invention	500 mg
Witepsol® H-15	balance

25 The foregoing invention has been described in some detail by way of illustration and example, for purposes of clarity and understanding. It will be obvious to one of skill in the art that changes and modifications may be practiced within the scope of the appended claims. Therefore, it is to be understood that the above description is intended to be illustrative and not restrictive. The scope of the invention should, therefore, be determined not with reference to the above description, but should instead be determined with reference to the following appended claims, along with the full scope of equivalents to which such claims are entitled.

WE CLAIM:

1. A compound of Formula (I):



5 wherein:

R¹ is benzoxazol-2-yl, oxazolo[4,5-b]pyridin-2-yl, 2-ethyl-[1,3,4]-oxadiazol-5-yl, 2-phenyl-[1,3,4]-oxadiazol-5-yl, 3-phenyl-[1,2,4]-oxadiazol-5-yl, 3-thien-3-yl-[1,2,4]-oxadiazol-5-yl, 3-pyridin-3-yl-[1,2,4]-oxadiazol-5-yl, 3-ethyl-[1,2,4]-oxadiazol-5-yl, 5-ethyl-[1,2,4]-oxadiazol-3-yl, or 2-methoxymethyl-[1,3,4]-oxadiazol-5-yl; and

10 R² is ethyl or *n*-propyl;









R³ is cyclohexylmethyl, 1-methylcyclohexylmethyl, cyclopentylmethyl, 1-methylcyclopentylmethyl, cyclopropylmethylsulfonylmethyl, cyclopropylmethylsulfonylmethyl, 2-phenylsulfanylethyl, 2-phenylsulfonylethyl, pyridin-2-ylmethylsulfonylmethyl, benzylsulfinylmethyl, benzylsulfonylmethyl, 2-(difluoromethoxy)-benzylsulfonylmethyl, or 2-chlorobenzyl;











15 R⁴ is methyl, phenyl, 4-fluorophenyl, isopropylamine, cyclopentylamine, tetrahydropyran-4-yl, morpholin-4-yl, or pyrrolidin-1-yl;


R⁵ is methylsulfonyl, 2,2,2-trifluoroethyl, ethoxycarbonyl, or pyridin-3-ylsulfonyl; or


20 R⁴ and R⁵ together with the atoms to which they are attached form 1,1-dioxo-benzo[d]isothiazol-3-yl or 1,1-dioxo-1,4-dihydro-λ⁶-benzo[1,2,4]thiadiazin-3-yl; or a pharmaceutically acceptable salts thereof.


2. A compound selected from the group consisting of:















or a pharmaceutically acceptable salt thereof.

3. A compound of formula:



4. A pharmaceutical composition comprising a compound of any of the Claims 1-3 in admixture with one or more suitable excipients.
5. A method for treating a disease in an animal mediated by cysteine proteases which method comprises administering to the animal a therapeutically effective amount of a compound of any of the Claims 1-3.
6. A method of treating a patient undergoing a therapy wherein the therapy causes an immune response in the patient comprising administering to the patient a compound of any of the Claims 1-3
- 10 7. The method of Claim 6 wherein the therapy involves treatment with a biologic.
8. The method of Claim 7 wherein the biologic is a protein or an antibody.
9. The method of Claim 8 wherein the biologic is Remicade®, Refacto®, Referon-A®, Factor VIII, Factor VII, Betaseron®, Epogen®, Embrel®, Interferon beta, Botox®, Fabrazyme®, Elspar®,
15 Cerezyme®, Myobloc®, Aldurazyme®, Verluma®, Interferon alpha, Humira®, Aranesp®, Zevalin® or OKT3.
10. A method of treating immune response in an animal that is caused by administration of a biologic to the animal which method comprises administering to the animal in need of such treatment a therapeutically effective amount of a compound of any of the Claims 1-3.
- 20 11. A method of conducting a clinical trial for a biologic comprising administering to an individual participating in the clinical trial a compound of any of the Claims 1-3 with the biologic.
12. A method of prophylactically treating a person undergoing treatment with a biologic with a compound of any of the Claims 1-3 to treat the immune response caused by the biologic in the person.
- 25 13. A method of determining the loss in the efficacy of a biologic in an animal due to the immune response caused by the biologic comprising administering the biologic to the animal in the presence

and absence of a compound of any of the Claims 1-3.

14. A method of improving efficacy of a biologic in an animal comprising administering the biologic to the animal with a compound of any of the Claims 1-3.

15. The method of Claim 5 wherein the cysteine protease is Cathepsin S.

5 16. The method of Claim 15 wherein the disease is psoriasis or Grave's exophthalmos.

ABSTRACT OF THE DISCLOSURE

The present invention is directed to compounds that are inhibitors of cysteine proteases, in particular, cathepsins B, K, L, F, and S and are therefore useful in treating diseases mediated by these proteases. The present invention is directed to pharmaceutical compositions comprising these 5 compounds and processes for preparing them.
